Navigation Links
Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
Date:11/20/2013

rt a future application for regulatory approval.

About Humacyte

Humacyte, Inc., a privately held company founded in 2005, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that are designed be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for a variety of patients, including those with vascular disease and those requiring hemodialysis. The company's proprietary technologies are designed to result in off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.

Forward-Looking Statement

Information in this news release contains "forward-looking statements" about Humacyte. These statements, including statements regarding management's projections relating to future results and operations, are based on, among other things, management's views, assumptions and estimates, developed in good faith, all of which are subject to known and unknown factors that may cause actual results, performance or achievements, or industry results, to differ materially from those expressed or implied by such forward-looking statements.

References

[1]https://www.kidney.org/kidneydisease/aboutckd.cfm
[2]http://www.ekha.eu/usr_img/info/factsheet.pdf
'/>"/>

SOURCE Humacyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
10. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
11. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... and extinctions around the world have been linked ... new research from the National Institute for Mathematical ... ranavirus, may also contribute. , In a ... which causes severe hemorrhage of internal organs in ... wood frogs if they are exposed to the ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... among those who apply the chemicals, study shows , ... pesticides have double the normal risk of developing a ... (monoclonal gammopathy of undetermined significance) and characterized by an ... monitoring because it can lead to multiple myeloma, a ...
... of Facebook, Twitter coincides with 30% drop in hours spent ... American kids and their parents are now spending more hours ... eroding the amount of time families spend together. , That,s ... week that families interact as group has fallen by nearly ...
... Power Plate(R) North America (PPNA), the global ... trend in fitness and beauty to the greater Los ... studio opening this month for the summer in Brentwood, ... machines, "Power Plate(R) - The Experience" will provide group ...
... stay up at night worrying whether they are going to develop ... and middle age is a lifetime away. As ... Feinberg School of Medicine have found that young adults (18 to ... a treadmill test -- are two to three times more likely ...
... scientists are among a multinational collaborative group to have ... European Union. The research will focus on ... common to all solid tumours. Hypoxia causes a ... resistant to radiotherapy and most forms of chemotherapy; as ...
... June 18 George Dahlman, senior vice president of ... testified today before the U.S. Senate Subcommittee on Defense ... cancer research program at the Department of Defense (DoD). ... determined that several blood cancers, including chronic lymphocytic leukemia ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Surging Internet Use Cutting Into Family Time 2Health News:Surging Internet Use Cutting Into Family Time 3Health News:Power Plate(R) Opens Cutting-Edge Studio in L.A. 2Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:$16.8 million study will breathe new life into cancer battle 2Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
... UltraFit PK System rede phines sharpness ... trephine program for penetrating keratoplasty. Advanced ... cutting edge to achieve the critical fit ... disposable and fully customized system enables surgeons ...
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
Medicine Products: